PTHS (Channel) Net earnings per share (EPS TTM)

Channel (PTHS) - corporate logo

Channel Therapeutics (PTHS) relies on external contractors for testing, minimizing its own physical assets and adhering to basic environmental standards in laboratories. This chart on the GURU.Markets platform reflects a price trend serving as an indicator where the EPS value is -25.20. Business prospects are based on the development of drugs for rare CNS pathologies and the probability of a merger with industry behemoths.

Channel - PTHS Earnings per share for the last twelve months (period 11/23/2025 - 11/15/2026)

PTHS (Channel Therapeutics Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
Market Price Channel|PTHS - Consensus Target
- business market valuation indicators:
Market Capitalization Channel Pharma|PTHS - Total Company Value
- shareholders' equity book value data:
Accounting Value of a Share Channel Therapeutics|PTHS - Company Book Value|Market-to-Book Ratio channeltherapeutics.com|PTHS - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Channel Therapeutics|PTHS - Long-Term Debt to Equity|Current Liabilities to Capital Channel Therapeutics|PTHS - Company Aggregate Debts|Debt to Net Assets Channel Therapeutics|PTHS - Company Long-Term Liabilities|Short-Term Debt Channel Therapeutics|Quick Liquidity Indicator channeltherapeutics.com
- financial results and valuation multiples details:
PTHS - Net Profit|Expected Net Income Channel Therapeutics|PTHS - P/E Multiple|Forward P/E Multiple Channel Pharma|PTHS - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Channel Pharma|PTHS - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Channel Therapeutics|PTHS - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months channeltherapeutics.com|PTHS - Earnings per share growth in current year|Net earnings per share growth forecast for next year Channel Therapeutics
- revenue and sales details:
PTHS - Company Sales|Company Future Revenue Channel|PTHS - Market Cap to Revenue|Price to Expected Revenue Ratio Channel
Fundamental company valuation:PTHS Channel
Flagship merchandise of Channel Therapeutics Corp

Channel Therapeutics' specialization in neurotherapy development and its reliance on partner payments render profit dynamics volatile. Analyzing the relative change in EPS YoY (ttm) allows for an assessment of net income per share growth rates over a rolling year, filtering out market noise and revealing the actual efficiency of investment capitalization, which is critical for evaluating the fundamental stability of the biopharmaceutical business.

Direct competitors

Net earnings per one share for the last twelve months Jazz Pharma|CYTK (Cytokinetics Inc.) - Net earnings per share for the last 12 months|PTC Bio (PTCT) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Scholar Rock|CNTA: Earnings per share for the trailing year|Earnings per share for the last twelve months Dyne Therapeutics (DYN)|EWTX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Rapport Pharma RAPP|Alumis Pharma - Earnings per share for the last twelve months|ZVRA - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Contineum Therapeutics, Inc.|LRMR: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Capricor Therapeutics CAPR|Net earnings per share for the last 12 months TRDA|Net earnings per one share for the last twelve months medicinova.com MNOV|Net earnings per share (EPS TTM) SER|Earnings per share for the last twelve months BTAI (BioXcel Therapeutics)|Earnings per share for the last twelve months ProMIS Neurosciences, Inc. PMN|APUS (Apimeds) - Earnings per one share for the last 12 months|AEON - Earnings per share for the last twelve months|Net earnings per share for the last four quarters NLS Pharmaceutics Ltd. NLSP|Bionomics Limited (BNOX) - Earnings per share for the last twelve months|fsdpharma.com - Earnings per share for the trailing year|RETA (reatapharma.com) - Net earnings per share (EPS TTM)